Treatment of two patients with erythrodermic psoriasis with ixekizumab during COVID-19 pandemic

Background
Erythrodermic psoriasis is the most severe form of psoriasis. Here, we report two cases of EP who achieved PASI 100 with the treatment of ixekizumab during Coronavirus disease-19 (COVID-19) pandemic.
Case summary
A female and a male patient with erythrodermic psoriasis applied to dermatology outpatient clinic of our hospital. Treatment with standard dose ixekizumab (160 mg sc at week 0 and then 80 mg sc every 2 weeks for 12 weeks) led to PASI 100 response in our first case after only 5 weeks and in our second case after 6 weeks.
Conclusion
To date, there have been six patients with EP who reached PASI 100 with ixekizumab treatment, one of them could achieve to this level earliest at week 6, one of them earliest at week 8 and four of them earliest at week 12, whereas our first case reached PASI 100 at week 5 and our second case reached at week 6. Our cases were deemed worthy of presentation because our female patient was the case with the fastest response to PASI 100 with ixekizumab, and our two cases were the first reported patients who reached PASI 100 during COVID-19 pandemic. Our patients continue ixekizumab treatment without any side effects and remain self-isolated at home.